Antihemophilic Factor Fc Fusion Protein Recombinant Brand Name– ELOCTATE
What is Antihemophilic Factor Fc Fusion Protein Recombinant
Antihemophilic Factor Fc Fusion Protein Recombinant is approved for adults and children with hemophilia A for control and prevention of bleeding episodes, management of bleeding during surgical procedures, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
The antihemophilic factor is linked to the Fc protein fragment of human IgG1, which prolongs factor circulation in the body and extends time between prophylactic infusions.
This product is not derived from human blood and contains no preservatives or added animal or human components. Recombinant antihemophilic factor, Fc fusion protein was FDA-approved in June 2014.
- bleeding prophylaxis
- hemophilia A
- surgical bleeding
For the management of hemophilia A (congenital Factor VIII deficiency)
- abdominal pain
- anaphylactoid reactions
- antibody formation
- chest pain (unspecified)
- injection site reaction
- clotting inhibitor titers
- factor VIII concentrations
- factor VIII inhibitors
- Factor VIIa, Recombinant